WaveMan · Form 4
Shah Rajeev M. insider trades
> Search tickers & screens ⌘K
LIVE

Shah Rajeev M. insider trades

Shah Rajeev M. has filed 41 Form 4s with the SEC that we hold, for Vor Biopharma Inc. (VOR) (Director, 10% owner), Cytek Biosciences, Inc. (CTKB) (Director), AN2 Therapeutics, Inc. (ANTX) (10% owner) and Acumen Pharmaceuticals, Inc. (ABOS) (Director, 10% owner), among 26 companies in all. Across all of them we count 38 purchases worth $314.0M and 24 sales worth $28.0M reported on Form 4. In the last 12 months: 8 purchases ($61.0M) and 21 sales ($26.5M). The largest single trade was a purchase of 3,828,400 shares of Septerna, Inc. worth $68.9M, dated 2024-10-28. The first filing on our record is dated 2021-07-06 and the latest 2026-06-11.

Vor Biopharma Inc. (VOR)

Director, 10% owner · 5 filings · 21 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-10-15S, sale reported on Form 48,384$256.1K2025-10-17
2025-10-15S, sale reported on Form 442,699$1.3M2025-10-17
2025-10-15S, sale reported on Form 446$1.4K2025-10-17
2025-10-15S, sale reported on Form 4234$7.3K2025-10-17
2025-10-16S, sale reported on Form 44$1252025-10-17
2025-10-16S, sale reported on Form 420$6272025-10-17
2025-10-16S, sale reported on Form 43,108$94.4K2025-10-17
2025-10-16S, sale reported on Form 415,826$480.5K2025-10-17
2025-10-16S, sale reported on Form 421,804$639.3K2025-10-17
2025-10-16S, sale reported on Form 4111,041$3.3M2025-10-17
2025-10-17S, sale reported on Form 434,284$998.4K2025-10-17
2025-10-17S, sale reported on Form 430,758$931.4K2025-10-17
2025-10-17S, sale reported on Form 46,040$182.9K2025-10-17
2025-10-17S, sale reported on Form 412,691$393.4K2025-10-17
2025-10-17S, sale reported on Form 42,492$77.3K2025-10-17
2025-10-17S, sale reported on Form 4174,594$5.1M2025-10-17
2026-04-08S, sale reported on Form 4130,862$2.2M2026-04-10
2026-04-08S, sale reported on Form 4353,242$5.8M2026-04-10
2026-04-09S, sale reported on Form 4135,201$2.2M2026-04-10
2026-04-10S, sale reported on Form 4828$13.0K2026-04-10
2026-04-22S, sale reported on Form 4165,150$2.6M2026-04-24

Cytek Biosciences, Inc. (CTKB)

Director · 4 filings · 12 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-02-17P, purchase reported on Form 4166,229$2.5M2022-02-22
2022-02-18P, purchase reported on Form 4166,229$2.3M2022-02-22
2022-02-22P, purchase reported on Form 4214,922$2.9M2022-02-22
2022-02-28P, purchase reported on Form 48,746$113.4K2022-03-02
2022-03-01P, purchase reported on Form 4294,864$3.8M2022-03-02
2022-03-02P, purchase reported on Form 4138,255$1.8M2022-03-02
2022-03-04P, purchase reported on Form 463,662$827.0K2022-03-08
2022-03-07P, purchase reported on Form 4337,901$4.3M2022-03-08
2022-03-08P, purchase reported on Form 4245,701$3.2M2022-03-08
2022-03-09P, purchase reported on Form 440,154$521.6K2022-03-11
2022-03-10P, purchase reported on Form 4256,992$3.3M2022-03-11
2022-03-11P, purchase reported on Form 4337,492$4.3M2022-03-11

AN2 Therapeutics, Inc. (ANTX)

10% owner · 2 filings · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-06-21P, purchase reported on Form 4302$2.4K2022-06-23
2022-08-03P, purchase reported on Form 41,809$13.5K2022-08-05
2022-08-04P, purchase reported on Form 4100$7992022-08-05

Acumen Pharmaceuticals, Inc. (ABOS)

Director, 10% owner · 2 filings · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-07-06P, purchase reported on Form 4115,668$1.9M2021-07-08
2021-07-06P, purchase reported on Form 41,759,332$28.1M2021-07-08

Black Diamond Therapeutics, Inc. (BDTX)

Director · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

ETNB

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Enliven Therapeutics, Inc. (IMRA)

10% owner · 2 filings · 5 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-10-20P, purchase reported on Form 411,342$44.8K2022-10-24
2022-10-21P, purchase reported on Form 448,100$188.6K2022-10-24
2022-10-24P, purchase reported on Form 426,460$103.5K2022-10-24
2022-12-08P, purchase reported on Form 410,600$39.8K2022-12-12
2022-12-09P, purchase reported on Form 419,299$75.8K2022-12-12

Jade Biosciences, Inc. (AVTE)

Director, 10% owner · 2 filings · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-07-02P, purchase reported on Form 42,785,714$39.0M2021-07-06
2024-06-17P, purchase reported on Form 4928,110$1.5M2024-06-20

Nkarta, Inc. (NKTX)

Director, 10% owner · 2 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2022-04-26P, purchase reported on Form 42,200,000$33.0M2022-04-28

STSA

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

ARS Pharmaceuticals, Inc. (SPRY)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Adicet Bio, Inc. (ACET)

10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Bicara Therapeutics Inc. (BCAX)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

CDTX

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

FMTX

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Fulcrum Therapeutics, Inc. (FULC)

10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Hemab Therapeutics Holdings, Inc. (COAG)

Director, 10% owner · 1 filing · 6 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-05-04P, purchase reported on Form 4133,750$2.4M2026-05-06
2026-05-04P, purchase reported on Form 42,541,250$45.7M2026-05-06
2026-05-05P, purchase reported on Form 410,268$256.7K2026-05-06
2026-05-05P, purchase reported on Form 487,143$2.1M2026-05-06
2026-05-06P, purchase reported on Form 453,407$1.3M2026-05-06
2026-05-06P, purchase reported on Form 414,611$347.3K2026-05-06

ICVX

Director, 10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-08-02P, purchase reported on Form 4171,766$2.6M2021-08-04
2021-08-02P, purchase reported on Form 42,494,900$37.4M2021-08-04

KALA BIO, Inc. (KALA)

10% owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-05-23S, sale reported on Form 41,250,000$812.5K2022-05-25
2022-05-24S, sale reported on Form 4144,805$73.9K2022-05-25
2022-05-25S, sale reported on Form 41,434,509$602.5K2022-05-25

Mineralys Therapeutics, Inc. (MLYS)

Director · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-03-27P, purchase reported on Form 4310,700$7.4M2026-03-31
2026-03-30P, purchase reported on Form 458,300$1.4M2026-03-31

Prelude Therapeutics Inc (PRLD)

10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Septerna, Inc. (SEPN)

Director, 10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2024-10-28P, purchase reported on Form 43,828,400$68.9M2024-10-30
2024-10-28P, purchase reported on Form 4341,600$6.1M2024-10-30

Solid Biosciences Inc. (SLDB)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

SpyGlass Pharma, Inc. (SGP)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Tyra Biosciences, Inc. (TYRA)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Werewolf Therapeutics, Inc. (HOWL)

Director, 10% owner · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2023-01-06P, purchase reported on Form 41,853,000$4.1M2023-01-10
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1619841) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms